To explore the effect of switching treatment from innovator infliximab (Remicade®) to infliximab biosimilar (Inflectra®, Remsima®) on efficacy, safety and immunogenicity in patients with rheumatoid arthritis (RA), spondyloarthritis (SpA) or…
ID
Bron
Verkorte titel
Aandoening
Biosimilar, Infliximab, Inflectra, Remsima
Ondersteuning
Sint Maartenskliniek Nijmegen
Maartenskliniek Woerden
Radboud University Medical Centre Nijmegen
Rijnstate Arnhem
Maartenskliniek Woerden
Radboud University Medical Centre Nijmegen
Rijnstate Arnhem
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The difference in mean DAS28-ESR and mean DAS28-CRP (for RA and PsA) and mean BASDAI (for SpA) between baseline and follow-up (after 6 and 12 months of treatment with the biosimilar) will be used as primary efficacy endpoint
Achtergrond van het onderzoek
Background: Taking into account the overall data from the PLANETRA and PLANETAS study, previous positive experiences with switching to a biosimilar, the viewpoint of relevant (inter)national stakeholders and the large cost difference, switching from Remicade to infliximab biosimilar in RA, SpA and PsA patients might be a sensible option. This should be done in shared decision making with the patient and should be monitored with caution. It is expected that in 2015 a substantial number of patients will switch from Remicade to infliximab biosimilar in daily clinical care. Since regulatory guidelines recommend close monitoring of patients who switch treatment to a biosimilar, we shall collect data on efficacy, safety and immunogenicity in daily clinical care.
Objective: To explore the effect of switching treatment from innovator infliximab (Remicade®) to infliximab biosimilar (Inflectra®, Remsima®) on efficacy, safety and immunogenicity in patients with RA, SpA or PsA in daily clinical care.
Study design: This is an exploratory observational controlled before after multicentre prospective cohort study.
Methods: Based on the treatment protocol of the hospitals, RA, SpA and PsA patients who are currently treated with Remicade will be informed about the option to switch to infliximab biosimilar. Both patients who will switch treatment to infliximab biosimilar (switch group) as patients who will not switch treatment (control group) will be asked to participate in this study. Data will be collected during the outpatient clinical visits performed in usual care during a 12 months follow-up. At baseline (day of the first infusion), patient characteristics and blood samples will be obtained. After 6 and 12 months (+/- 2 months) follow-up data on efficacy will be collected. Safety will be evaluated on the day of each infusion. After 6 and 12 months follow-up (+/- 2 months) a blood sample will be obtained on a scheduled infusion day.
Doel van het onderzoek
To explore the effect of switching treatment from innovator infliximab (Remicade®) to infliximab biosimilar (Inflectra®, Remsima®) on efficacy, safety and immunogenicity in patients with rheumatoid arthritis (RA), spondyloarthritis (SpA) or psoriatic arthritis (PsA) in daily clinical care
Onderzoeksopzet
Data will be recorded at baseline and after 6 and 12 months (+/- 2 months) of treatment.
Onderzoeksproduct en/of interventie
Based on the treatment protocol of the hospitals, RA, SpA and PsA patients who are currently treated with Remicade will be informed about the option to switch to infliximab biosimilar. Both patients who will switch treatment to infliximab biosimilar (switch group) as patients who will not switch treatment (control group) will be asked to participate in this study. Data will be collected during the outpatient clinical visits performed in usual care during a 12 months follow-up. At baseline (day of the first infusion), patient characteristics and blood samples will be obtained. After 6 and 12 months (+/- 2 months) follow-up data on efficacy will be collected. Safety will be evaluated on the day of each infusion. After 6 and 12 months follow-up (+/- 2 months) a blood sample will be obtained on a scheduled infusion day.
Publiek
Alfons den Broeder
Nijmegen 6500GM
The Netherlands
+31243659276
a.denbroeder@maartenskliniek.nl
Wetenschappelijk
Alfons den Broeder
Nijmegen 6500GM
The Netherlands
+31243659276
a.denbroeder@maartenskliniek.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. A clinical diagnosis of either RA, SpA or PsA.
2. Currently being treated with Remicade (1 or more infusions)
3. > 18 years of age
4. Ability to read and communicate well in Dutch
5. Informed consent
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
None
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL5139 |
NTR-old | NTR5279 |
Ander register | Submitted to CCMO: not WMO liable : 2015-1867 NIET WMO |